Document is current
Any future updates will be listed below
-
Authors
Chen, Yue https://orcid.org/0000-0003-0390-4606
Hu, Chao
Cao, Xiaotao
Men, Yuchun
Wang, Ying
Zhang, Ruijie
Guan, Hongyu
Shi, Lihong
Liu, Fang
Miao, Jia
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct06883656 at ClinicalTrials.govDocuments that mention this clinical trial
Pharmacokinetics, Pharmacodynamics and Safety of Fultagliptin Benzoate Tablets, a DPP-4 Inhibitor, in Patients With Varying Degrees of Renal Insufficiency and Matched Healthy Volunteers: A Phase I Clinical Trial
https://doi.org/10.1007/s40262-026-01622-8
-
Funding
Funding for this research was provided by:
Shenzhen Salubris Pharmaceuticals Co., Ltd
- License Information
-
More Information
Article History
Received: 19 June 2025
Accepted: 11 January 2026
First Online: 9 February 2026
Declarations
:
: Ruijie Zhang and Hongyu Guan reported being employed at Shenzhen Salubris Pharmaceuticals. The remaining authors declare no competing interests.
: The data that support the findings of this study are available from the corresponding authors upon reasonable request.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee for West China Hospital, Sichuan University (China).
: Informed consent was obtained from all patients included in the study.
: Not applicable.
: Not applicable.
: All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Jia Miao, Fang Liu, Chao Hu, Xiaotao Cao, Yuchun Men, and Ying Wang. The first draft of the manuscript was written by Yue Chen and Jia Miao, Ruijie Zhang, Hongyu Guan, and Lihong Shi commented on previous versions of the manuscript. All authors read and approved the final manuscript.
